Tryptophan
Other Antidepressants
Sold as TRYPTAN · AMINOVEN 8
- Drug class
- Other Antidepressants
- Availability
- Over-the-counter
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 18
- FDA reports (12 mo)
- 73
Overview
Plain-language summary, compiled from the cited regulatory records
Tryptophan is an amino acid that falls under the drug class of other antidepressants [1]. It is approved for the temporary relief of symptoms associated with anxiety, bloating, constipation, mood swings, lethargy, difficulty sleeping, and fatigue [1].
In the past 12 months, there have been 73 adverse event reports concerning tryptophan [2]. The most frequently reported reactions include fatigue, nausea, off-label use, headache, and dizziness [2]. Tryptophan is available under various brand names in this market.
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 13 | April 1, 2026 |
| GB United Kingdom | MHRA | 3 | April 17, 2026 |
| US United States | FDA | 2 | January 8, 2026 |
CACanada· Health Canada
13 products
Uses
TRYPTAN is indicated: as a valuable adjunct to antidepressant drug treatment in the management of patients suffering from depressive disorders (bipolar affective disorders).
How to take
GBUnited Kingdom· MHRA
3 products
Uses
For supply of amino acids as part of a parenteral nutrition regimen. Amino acid solutions should be administered generally in combination with adequate amount of energy supplements.
How to take
USUnited States· FDA
2 products
Uses
INDICATIONS:
For temporary relief of anxiety, bloating, constipation, mood swings, lethargy, inability to sleep and fatigue
How to take
Drug interactions
Known interactions involving Tryptophan. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 00654531 · revised January 6, 2026
- [2]MHRA (UK) · PL088280127 · revised June 20, 2025
- [3]FDA DailyMed · 080c91ec-4800-42… · revised September 29, 2016 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.